<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10283">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02973087</url>
  </required_header>
  <id_info>
    <org_study_id>071301</org_study_id>
    <nct_id>NCT02973087</nct_id>
  </id_info>
  <brief_title>rVWF IN PROPHYLAXIS</brief_title>
  <official_title>A Prospective, Phase 3, Open Label, International Multicenter Study on Efficacy and Safety of Prophylaxis With rVWF in Severe Von Willebrand Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta US Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxalta US Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 3 study is to investigate the efficacy and safety, including
      immunogenicity and thrombogenicity of prophylactic treatment with recombinant von Willebrand
      factor (rVWF) in subjects with severe von Willebrand disease (VWD).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prospectively recorded annualized bleeding rate (ABR) for spontaneous (not related to trauma) bleeding episodes during prophylactic treatment with (rVWF) and the participants' historical ABR for spontaneous bleeding episodes during on-demand treatment</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>recombinant von Willebrand factor (rVWF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction of annualized bleeding rate (ABR) for spontaneous (not related to trauma) bleeding episodes during prophylaxis relative to the participants' own historical ABR during on-demand treatment</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with zero bleeds during prophylactic treatment with recombinant von Willebrand factor (rVWF)</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions of recombinant von Willebrand factor (rVWF) and ADVATE per month during on-demand treatment</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions of recombinant von Willebrand factor (rVWF) and ADVATE per year during on-demand treatment</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total weight adjusted consumption of recombinant von Willebrand factor (rVWF) and ADVATE per month on-demand treatment</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total weight adjusted consumption of recombinant von Willebrand factor (rVWF) and ADVATE per year on-demand treatment</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thromboembolic events</measure>
    <time_frame>Throughout the study period of approximately 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hypersensitivity reactions</measure>
    <time_frame>Throughout the study period of approximately 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who develop neutralizing antibodies to recombinant von Willebrand factor (rVWF) and Factor VIII (FVIII)</measure>
    <time_frame>Throughout the study period of approximately 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who develop total binding antibodies to recombinant von Willebrand factor (rVWF) and Factor VIII (FVIII)</measure>
    <time_frame>Throughout the study period of approximately 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who develop antibodies to Chinese hamster ovary (CHO) proteins, mouse immunoglobulin G (IgG) and rFurin</measure>
    <time_frame>Throughout the study period of approximately 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Incremental recovery (IR)</measure>
    <time_frame>30 minutes pre-infusion; and post-infusion at 30 minutes and 1, 6, 12, 24. 48, and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Terminal half-life (T1/2)</measure>
    <time_frame>30 minutes pre-infusion; and post-infusion at 30 minutes and 1, 6, 12, 24. 48, and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Mean residence time (MRT)</measure>
    <time_frame>30 minutes pre-infusion; and post-infusion at 30 minutes and 1, 6, 12, 24. 48, and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the curve/dose (AUC/dose)</measure>
    <time_frame>30 minutes pre-infusion; and post-infusion at 30 minutes and 1, 6, 12, 24. 48, and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under moment curve/dose (AUMC/dose)</measure>
    <time_frame>30 minutes pre-infusion; and post-infusion at 30 minutes and 1, 6, 12, 24. 48, and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Volume of distribution at steady state (Vss)</measure>
    <time_frame>30 minutes pre-infusion; and post-infusion at 30 minutes and 1, 6, 12, 24. 48, and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Clearance (CL)</measure>
    <time_frame>30 minutes pre-infusion; and post-infusion at 30 minutes and 1, 6, 12, 24. 48, and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions of recombinant von Willebrand factor (rVWF) and ADVATE (rFVIII) per spontaneous bleeding episode (BE)</measure>
    <time_frame>Throughout the study period, up to approximately 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions of recombinant von Willebrand factor (rVWF) and ADVATE (rFVIII) per traumatic bleeding episode (BE)</measure>
    <time_frame>Throughout the study period, up to approximately 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted consumption of recombinant von Willebrand factor (rVWF) and ADVATE (rFVIII) per spontaneous bleeding episode (BE)</measure>
    <time_frame>Throughout the study period, up to approximately 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted consumption of recombinant von Willebrand factor (rVWF) and ADVATE (rFVIII) per traumatic bleeding episode (BE)</measure>
    <time_frame>Throughout the study period, up to approximately 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall hemostatic efficacy rating at resolution of bleed</measure>
    <time_frame>Throughout the study period, up to approximately 22 months</time_frame>
    <description>Using a 4-point scale: Excellent, Good, Moderate, None</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>All Study Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>von Willebrand factor (Recombinant)</intervention_name>
    <arm_group_label>All Study Participants</arm_group_label>
    <other_name>VONVENDI</other_name>
    <other_name>BAX111</other_name>
    <other_name>rVWF</other_name>
    <other_name>BAX 111</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antihemophilic Factor (Recombinant)</intervention_name>
    <arm_group_label>All Study Participants</arm_group_label>
    <other_name>ADVATE</other_name>
    <other_name>Recombinant Factor VIII</other_name>
    <other_name>rFVIII</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant has a documented diagnosis of severe von Willebrand disease (VWD)
             (baseline Von Willebrand factor: Ristocetin cofactor activity (VWF:RCo) &lt;20 IU/dL)
             with a history of requiring substitution therapy with von Willebrand factor
             concentrate to control bleeding

               1. Type 1 (VWF:RCo &lt;20 IU/dL) or,

               2. Type 2A (as verified by multimer pattern), Type 2B (as diagnosed by genotype),
                  Type 2M or,

               3. Type 3 (VWF:Ag â‰¤3 IU/dL).

          2. Diagnosis is confirmed by genetic testing and multimer analysis, documented in
             patient history or at screening.

          3. Participant currently receiving on-demand treatment for whom prophylactic treatment
             is recommended according to standard of care at the center.

          4. Has â‰¥3 documented spontaneous bleeds requiring von Willebrand factor (VWF) treatment
             during the past 12 months

          5. Availability of records to reliably evaluate type, frequency and treatment of
             bleeding episodes during 12 months of on-demand treatment prior to enrollment.

          6. Participant is â‰¥18 years old at the time of screening and has a body mass index â‰¥15
             but &lt;40 kg/m^2.

          7. If female of childbearing potential, participant presents with a negative blood/urine
             pregnancy test at screening and agrees to employ adequate birth control measures for
             the duration of the study.

          8. Participant is willing and able to comply with the requirements of the protocol.

        Exclusion Criteria:

          1. Participant has been diagnosed with Type 2N von Willebrand disease (VWD), pseudo VWD,
             or another hereditary or acquired coagulation disorder other than VWD (eg qualitative
             and quantitative platelet disorders or elevated prothrombin time (PT)/ international
             normalized ratio (INR) &gt;1.4).

          2. Participant has received prophylaxis treatment in the 12 months prior to screening
             (including those who received treatment once a month for menorrhagia but were not
             treated for any other bleeds).

          3. Participant is currently receiving prophylaxis treatment.

          4. Participant has a history or presence of a VWF inhibitor at screening.

          5. Participant has a history or presence of a Factor VIII (FVIII) inhibitor with a titer
             â‰¥0.4 BU (by Nijmegen modified Bethesda assay) or â‰¥0.6 Bethesda Unit (BU) (by Bethesda
             assay).

          6. Participant has a known hypersensitivity to any of the components of the study drugs,
             such as to mouse or hamster proteins.

          7. Participant has a medical history of immunological disorders, excluding seasonal
             allergic rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies.

          8. Participant has a medical history of a thromboembolic event.

          9. Participant is human immunodeficiency virus (HIV) positive with an absolute Helper T
             cell (CD4) count &lt;200/mm^3.

         10. Participant has been diagnosed with significant liver disease as evidenced by any of
             the following: serum Alanine aminotransferase (ALT) 5 times the Upper limit of normal
             (ULN); hypoalbuminemia; portal vein hypertension (e.g., presence of otherwise
             unexplained splenomegaly, history of esophageal varices).

         11. Participant has been diagnosed with renal disease, with a serum creatinine level â‰¥2.5
             mg/dL.

         12. Participant has a platelet count &lt;100,000/mL at screening.

         13. Participant has been treated with an immunomodulatory drug, excluding topical
             treatment (e.g., ointments, nasal sprays), within 30 days prior to signing the
             informed consent.

         14. Participant is pregnant or lactating at the time of enrollment.

         15. Participant has cervical or uterine conditions causing menorrhagia or metrorrhagia
             (including infection, dysplasia).

         16. Participant has participated in another clinical study involving another
             Investigational product (IP) or investigational device within 30 days prior to
             enrollment or is scheduled to participate in another clinical study involving an IP
             or investigational device during the course of this study.

         17. Participant has a progressive fatal disease and/or life expectancy of less than 15
             months.

         18. Participant is identified by the investigator as being unable or unwilling to
             cooperate with study procedures.

         19. The subject has a mental condition rendering him/her unable to understand the nature,
             scope and possible consequences of the study and/or evidence of an uncooperative
             attitude.

         20. Participant is in prison or compulsory detention by regulatory and/or juridical
             order.

         21. Participant is member of the study team or in a dependent relationship with one of
             the study team members which includes close relatives (i.e., children,
             partner/spouse, siblings and parents) as well as employees.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Sytkowski, MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_contact>
    <last_name>Sanhita Abrol, PhD</last_name>
    <email>sanhita.abrol1@shire.com</email>
  </overall_contact>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 22, 2016</lastchanged_date>
  <firstreceived_date>November 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
